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Abstract 
It is a common perception that European public-funded research fails to commercialize their discoveries, in contrast 
to the perceived success of their American counterparts. This resulted in policies aimed at improving the 
commercialization of European publicly-funded research, including the establishment of Technology Transfer 
Offices (TTOs). Recent surveys on the activities of these TTOs show that although European public-funded research 
lags behind the United States in patent applications and grants, they produce more start-ups, and have comparable 
results for the number of licenses executed. Steps to improve the international comparability of TTO surveys could 
provide useful new indicators for policy development. However, this will also require indicators for knowledge 
transfer through informal 'open science' methods." 
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1. Introduction 
Over the past decade, innovation policy in many OECD countries has stressed the need to 
improve the commercialization of research results from ‘public science’ institutions such as 
universities and government research institutes. Within Europe, this policy focus is partly due to 
a perception that Europe has failed to benefit from its substantial investments in public research, 
in contrast to the American experience, where university research results are believed to lie 
behind the creation of several globally competitive firms and blockbuster products ranging from 
pharmaceuticals to computer hardware and software. Another measure of American success in 
commercializing public science is the substantial licensing income that universities such as 
Stanford, Columbia, MIT and the University of Florida have earned from patenting their 
inventions.  
 
The policy discussion in Europe frequently refers to a ‘European Paradox’ of high public 
expenditure on research with few visible commercial benefits. A long-standing explanation for 
the paradox is a failure of public science institutes in Europe to actively commercialize their 
discoveries (EC, 1995). The causes of this failure have been linked in policy documents to a 
wide range of factors, including a lack of entrepreneurial spirit among scientists, barriers to the 
ability of public sector scientists to move to the private sector on a temporary basis to develop 
their discoveries, and to poor intellectual property rights for university inventions. Alternative 
explanations of the European Paradox, based on differences in the commercial potential of public 
research conducted in Europe versus the United States (Dosi et al, 2005), have not attracted 
much attention in the policy community. 
 
European governments have responded to the European Paradox by introducing policies to 
promote commercialization, such as university courses on entrepreneurship for future academics, 
and a range of other programmes to encourage technology transfer by promoting formal 
contractual relationships between the business sector and public science. These include subsidies 
for the establishment of technology transfer offices (TTOs) at universities, changes in IPR 
regulations to encourage universities to patent and license inventions, and requirements for 
universities to obtain a higher share of their research funding from the private sector (Callan and 
Cervantes, 2006).  
 
To date, there are very few national or internationally comparable indicators within Europe for 
evaluating the success of policies to promote the commercialization of public science. 
Internationally comparable indicators would be particularly useful for determining if a “failure of 
commercialization” is the cause of the European Paradox, or if other possible factors should 
receive more attention.  
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Potential indicators of relevance to the commercialisation of research by public science 
institutions range from citations to the scientific literature in business patents to the economic 
impacts of public science in terms of employment or value-added. Economic impact indicators 
are the most useful of all measures, but they are difficult to obtain and generally suffer from long 
lag times between public investment and outcomes. Consequently, they are not very useful for 
assessing the short and medium term effects of policies to encourage commercialisation. 
 
Indicators of value to policy must be capable of measuring the commercial potential of public 
science results or, preferably, the current use of the outputs of public science by firms. As Figure 
1 illustrates, firms acquire these outputs through two main pathways: freely available “open 
science” accessed by reading journal articles, attending academic conferences, or informal 
contacts between researchers in academia and business, and through formal relationships such as 
contract research or licensing. With the exception of citations to scientific articles in patents 
(Jaffe et al, 1993; Malo and Geuna, 2000)2, the use of open science by firms to develop 
innovations rarely leaves a visible trace that can be readily identified and measured. Innovation 
surveys, such as the CIS in Europe, obtain data on the subjective value of public science to firms, 
but do not separate access to research findings through open science from access through formal 
relationships.  
 
Formal relationships between firms and public science leave visible traces such as licensing or 
contract agreements that are more easily measured than open science. These traces are also 
directly relevant to current policies to encourage academic entrepreneurship and to permit public 
science institutes to obtain intellectual property rights (IPR) for discoveries with commercial 
potential. Another advantage is that indicators for the commercial potential of public science 
discoveries (invention disclosures and patenting), plus indicators for the use of public science 
outputs by firms (licensing and start-up establishments), can be obtained from a comparatively 
small number of technology transfer offices (TTOs) that serve public science institutions, rather 
than needing to survey a large number of firms about their use of the results of public science3. 
 
Insert figure 1 here. 
 
Data on the commercialization of public science have been collected on a consistent basis from 
the 1990s for two countries, the United States and Canada. The Association of University 
Technology Managers (AUTM) has collected data on American TTOs since 1991 and on an 
annual basis since 1996, with the most recent results available for fiscal year 2004 (AUTM, 
                                                 
2
 This method is not entirely accurate because the cited research is often included by the patent examiner rather than 
by the patent applicant. In addition, a cited paper can be included to build a patent claim, without the cited research 
contributing to the invention.  
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2005). Statistics Canada first surveyed Canadian universities in 1998 and on an annual basis 
since 2003, with complete results available for 2004 (Read, 2005; Read, 2006). Similar data are 
available for Australia for 2000, 2001 and 2002 for universities and other public research 
institutes (Commonwealth of Australia, 2004). All of these surveys collect data on both the 
commercial potential of public science and the use by firms of public science outputs.  
 
A main challenge for producing comparable indicators is to find a relevant denominator to 
normalize outputs from public science systems that vary enormously in size. There are two 
potential options, the number of researchers and the number of research expenditures, but the 
latter is more widely available.  
 
Relevant data for Europe on the commercialization of public science have not been available 
until recently. Between 2001 and 2002, the OECD ran a multi-country survey of the technology 
transfer activities of universities and government research institutes in thirteen OECD countries, 
including eight in Europe (OECD 2002; OECD 2003), but inter-country comparisons were 
severely hampered by a lack of good denominators such as R&D expenditures or the number of 
researchers4. The ProTon study for fiscal year 2004 obtained relevant output data from 172 
European public science institutes (Conesa et al, 2004), but did not provide results for a 
denominator5. 
 
Three recent surveys provide European data that are comparable to the AUTM, Australian and 
Canadian surveys. Two studies provide results for the UK (UNICO, 2005; HEFCE, 2006)6 while 
the third provides results for public science institutes across Europe (Arundel and Bordoy, 2006).  
 
In this paper we use the results of these six surveys to explore the possibilities and problems for 
developing internationally comparable output indicators for the commercialization of public 
science. The main purpose of the analysis is to illustrate what could be done, at relatively low 
cost, to fill an important gap in internationally comparable innovation indicators. This paper 
builds on preliminary work in several of these surveys to develop comparable indicators based 
on outputs per unit of R&D expenditures, but we provide a deeper analysis of the problems in 
using this approach to construct comparable indicators and suggest several solutions. We also 
identify additional survey questions that could provide valuable complementary information.  
                                                                                                                                                             
3
 The distinction between commercial potential and actual use indicators is in line with the one described in 
Hawkins et al. (2006) between output and outcome indicators. 
4
 The OECD study used the number of patents or licenses obtained per TTO, but this is unlikely to produce 
comparable indicators because of large differences in the number of researchers or research expenditures per public 
science institute. 
5
 The study collected data on the number of academics per institution but did not provide these data in a usable form.  
6
 In addition, a 2002 survey in the UK collected similar data for about 50 universities (Chapple et al 2005, Lockett 
and Wright, 2005) 
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2. Data sources and methodology 
All surveys collect data on research expenditures and on three output indicators for the 
commercial potential of public science discoveries (invention disclosures, patent applications 
and patent grants) and on three indicators for the use of public science by firms (licenses 
executed, start-ups established, and gross license revenue). 
 
In the spring of 2006, on behalf of the European ASTP, we conducted a survey of ASTP 
members representing public sector institutions such as universities, academic hospitals, and 
government or non-profit research institutes (Arundel and Bordoy, 2006). The survey response 
rate was 59%, with 101 replies from respondents that met the survey eligibility criteria. The 
respondents were based in 22 European countries.7 Seventy-four of the eligible respondents 
handled the technology transfer activities of a university while 27 represented government 
research institutes or hospitals.  
 
The ASTP membership represents approximately 19% of an estimated 1,000 public science 
institutes (universities and government research organisations combined) in the European union 
(Conesa et al, 2004), with survey responses available for approximately 10% of them.8 
 
The United States has an estimated 2,500 universities, but many are liberal arts colleges that are 
unlikely to develop patentable discoveries. Limited to universities that offer science and 
engineering (S&E), 1,521 offer bachelors degrees in S&E, 826 offer Masters level degrees in 
S&E, and 345 offer Doctorate level degrees in S&E (NSF, 2006). The fiscal 2004 AUTM survey 
obtained responses from 33 research institutes, most of which are hospitals, and from 164 
universities, or a minimum of 11% of American universities that offer science and engineering 
degrees (using bachelor level granting institutions).  
 
The 197 AUTM respondents included 96 of the top 100 American research universities. 
According to the AUTM report, these universities accounted for 87% of federal and industry-
financed research expenditures by American universities (the study does not report data for state 
sponsored research). 
 
The ASTP and AUTM surveys are limited to a self-selected group of association members, 
whereas the other four surveys were sent to almost all members of their target population of 
universities, research hospitals or other public research institutes.  
                                                 
7
 Ten or more valid responses were received from Denmark, the Netherlands and the United Kingdom, while 
between five and nine valid responses were obtained from Belgium, Finland, France, Germany, Greece, and 
Switzerland. 
8
 The ASTP survey obtained responses from 11% of all universities in seven countries where precise data on the 
number of universities are available: Italy, Spain, Switzerland, Norway, Portugal, the United Kingdom and the 
Netherlands.  
9 
 
The Canadian survey by Statistics Canada was sent to all members of the Association of 
Universities and Colleges of Canada (AUCC), which covers most universities granting a 
Bachelors level degree or higher, and to all known research hospitals. The survey response rate 
was 83% for universities and 63% for the hospitals. Results were obtained for 73 universities and 
24 hospitals.  
 
The UNICO survey for the UK appears to have been sent to all degree granting universities and 
major government research institutes. Although 44% of the target population did not respond, the 
study notes that responses were received from 47 of the top 50 UK universities in terms of 
research income for 2004. No final breakdown is given of the number of responses from 
universities versus other types of public institutions. The second UK survey (HEFCE, 2006) was 
only sent to universities and obtained responses from all of its target population for academic 
year 2003/04. 
 
2.1 Comparability issues 
Several differences in the design of the six surveys could reduce comparability. These include 
differences in the target populations, the questionnaires, and in the treatment of item non-
response.  
 
Target populations 
International comparability will be maximized if each study receives responses from all 
universities, all government research institutes, and all hospitals. This would prevent possible 
biases that could occur by preferentially surveying or obtaining a higher response rate from 
research-intensive institutions that are likely to perform better on the output indicators than 
second or third-tier institutions. The UK HEFCE survey for 2003/04 comes closest to this goal 
by obtaining results for all universities, followed by the Statistics Canada results for universities. 
In contrast, the ASTP and AUTM survey results are likely to be biased towards institutes with 
above average performance, although an evaluation of the respondent institutions suggests that 
the ASTP survey is less biased in this respect than the AUTM survey (Arundel and Bordoy, 
2006).  
 
Another difference in the survey populations that will influence comparability is the proportion 
of non-university institutes in the respondent samples, which accounts for between zero and 44% 
of the responses. These differences matter because of variations in performance by type of 
institution and by country. In the ASTP sample, non-university institutes out-perform 
universities on patent applications, patent grants, licenses executed and license income. 
Performance differences by the type of institution were also found in the OECD study (OECD, 
2003). In contrast, there is very little difference in the performance of universities and other 
10 
research institutes in the AUTM sample. One option is to limit the results to universities, but the 
relevance of this approach depends on the role of non-university institutions in national public 
research efforts. Only providing results for universities would fail to capture the 
commercialisation of public science in countries, such as Australia, that invest heavily in 
government research institutes. To avoid these problems, we provide results for all public 
science institutes combined and for universities only. 
 
TTO coverage of activities 
In countries such as Italy where patent rights are held by the inventor, the TTO may not be aware 
of all patents linked to a university invention. The PATVAL study, based on a patent database 
analysis of university patents between 1992 and 1997 in the Netherlands, the UK, Spain, 
Germany, France and Italy, found that well over half of patents with a university inventor were 
not owned by the university (Verspagen, 2006). This is one argument for tracing university 
patents through TTOs rather than patent databases, since TTOs can assist with the patenting of 
inventions that are not owned by the university. Furthermore, as European TTOs develop 
expertise over the time, the share of university patenting that they are aware of is likely to 
increase. The ASTP study asks TTOs managers to estimate the percentage of all patent 
applications by researchers at their affiliated institution that were handled by their office in 2006 
(Arundel and Bordoy, 2006). On average, 91% of patent applications were handled by TTOs.  
 
Variable definitions 
International comparability will be affected by different definitions of both outputs and research 
expenditures.  
 
A problem with the output measures is differences in how patent grants are counted. The AUTM 
study is limited to patents granted by the USPTO. This is likely to account for almost all 
patenting among the respondents, since very few patent applications are likely to be made only 
outside of the United States. Conversely, some patent applications by European public science 
institutes are only made outside of the home country (Arundel and Bordoy, 2002; OECD, 2003). 
For this reason, the ASTP study limits the definition of patent grants to ‘technically unique 
patents” to prevent multiple counting of an invention that is patented in more than one 
jurisdiction9. This should improve comparability with the AUTM results.  
 
                                                 
9
 The ASTP survey asked respondents to give the number of ‘technically unique patents that were granted to your 
institution”. A technically unique patent grant was defined in the question as “for one invention only. A patent for 
the same invention in two or more countries is one technically unique patent”. ‘Logical data and outlier checks, 
followed up by telephone calls, showed that the definition of a patent grant in the ASTP questionnaire was 
misunderstood by a few respondents who gave the total number of patents that were granted in all jurisdictions, 
rather than the number of technically unique patents. This led to substantial over reporting of patent grants, which 
was corrected using information collected in the follow-up. 
11 
The number of patent grants reported in the Australian, Canadian and both UK studies does not 
exclude multiple counting of granted patents for the same invention. In the Canadian and 
UNICO studies the same invention can be counted up to three times (in the domestic country, the 
United States, and all other countries combined), with the data suggesting substantial multiple 
counting. In the Australian study, patents can be counted in both Australia and the United States. 
To improve comparability, we limit the counts to the region or country with the largest number 
of patent grants. This is the United States for Canada, the UK for the UNICO and the HEFCE 
studies, and Australia for the Australian study. This will result in an underestimate of the true 
number of patent grants for these countries. 
 
The problem with multiple patent counts does not occur for patent applications in the AUTM, 
Canadian, ASTP and UNICO studies as all four surveys limit them to priority applications. 
However, the Australian study includes both applications in Australia and in the United States, 
and the HEFCE study provides the total number of patent applications and the number of those 
applied abroad, which does not prevent double counts. The Australian results are limited to 
Australian applications and the HEFCE results given below subtract the number of foreign 
applications from the total. 
 
Most of the surveys count all types of license agreements and license income from all types of 
IPR, for example from patents, material transfer agreements, copyright, etc. Conversely the 
AUTM survey excludes license income from software and biological material end-user licenses 
under $1000 and income received from material transfer agreements.  
 
Differences in the definition of research expenditures will have a significant impact on 
comparability because this statistic is the denominator for all indicators. Table 1 summarizes the 
different definitions in use and estimates if the definition will over or under estimate research 
expenditures compared to the AUTM study for the United States. An overestimate of research 
expenditures compared to the AUTM study will reduce the number of outputs per unit of 
research expenditures and therefore underestimate relative performance compared to the United 
States. Relative performance with the AUTM is likely to be underestimated for Europe, the 
HEFCE study, and for Australia, and overestimated for Canada. 
 
Insert table 1 here. 
 
Treatment of missing values 
The comparability of standardized performance indicators based on outputs per unit of research 
expenditures depends on how each study manages missing values, due to a reporting institution 
not answering a specific output question such as the number of patents granted in the relevant 
year. This can be a serious issue. In the ASTP survey, the share of missing values for the output 
12 
questions varied from a low of 18% for the number of start-ups to a high of 45% for the amount 
of license income earned. We adjust for missing values in the calculation of standardized 
performance indicators for the ASTP study by excluding respondents that did not answer both 
the output question and the question on total research expenditures. 
 
Missing values could have been less of a problem in the other five studies, but it is impossible to 
know since none provide the percentage of missing values for specific questions. The Canadian 
survey notes that some missing values are imputed, but provides no other details. From the count 
data given in the Australian study, it appears that there either were no missing values (highly 
unlikely) or that all missing values were imputed. 
 
We calculate standardized performance indicators for Canada, Australia, the United States and 
the UK by dividing the total reported outputs by the total reported research expenditure. This will 
underestimate performance if the research expenditure data are complete but some respondents 
do not report specific outputs, or overestimate performance if the output data are complete but 
some expenditure data are missing. Furthermore, missing data for either research expenditures or 
outputs for a small number of major respondent institutions can distort the results, since the 
distribution of both outputs and expenditures is highly skewed in all five surveys. As an 
example, failing to account for missing values in the ASTP survey for Europe, for instance by 
using the aggregated research results in Table 2 to calculate the indicators, would increase 
European performance by between 25% and 72%, depending on the output variable. This 
highlights the importance of adequately accounting for missing data. 
 
Insert table 2 here. 
 
3. Results 
Table 2 summarizes the main results of each of the six surveys. All financial data are given in 
US dollar purchasing power parities (PPP$), using OECD data on PPPs for Canada, Australia 
and each European country for the relevant year. 
 
Figure 2 gives five standardized performance indicators per 100 million US PPP$ of research 
expenditures from five surveys that include both universities and other types of public research 
institutes. The results for Europe and Australia (except for patent applications are limited to 
respondents that reported both research expenditures and each output, whereas the other 
performance indicators can be calculated from the aggregated data in Table 1.  
 
Insert figure 2 here. 
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As noted above, the indicators in Figure 2 are unlikely to be fully comparable, due to differences 
in the target population, the definition of each output and of R&D expenditures, and differences 
in the treatment of missing values. With this caveat, the United States is the performance leader 
for only one indicator, patent grants, and Canada leads on patent applications. The UK leads for 
the other three indicators, but we suspect that this might be due to a lack of adjustment for 
missing values. If the UK is excluded, Europe leads on licenses executed and start-up 
establishments.  
 
A sixth performance indicator is gross annual license revenue as a percentage of total annual 
research expenditures. This indicator should be of particular interest in countries where a policy 
goal is to increase non-governmental funding of university research, since some license revenue 
is often returned to the institute to fund research. The share of license revenue as a percentage of 
reported research expenditures is 1.0% for the UK10, 1.01% for Canada, 1.2% for Australia, 
3.0% for Europe (ASTP), and 3.5% for the United States. In all cases license revenue is a meager 
source of funding for research, particularly since part of license revenue often goes to the 
inventor, while another part is used to cover TTO expenses. 
 
Figure 3 gives results for universities only11, which are similar to those in Figure 2 for all 
institutes combined12. The United States leads on patent grants and Canada is the performance 
leader for patent applications. The UK leads for invention disclosures, licenses executed13 and, 
together with Europe, for start-ups. The UK performs much better for patent grants and patent 
applications when only universities are considered. However, this result could be due to multiple 
patent counts in the HEFCE study.  Of note, European performance on start-ups increases from 
1.6 per 100 million US PPP$ for all institutes to 2.8 for only universities. For universities, the 
share of license revenue as a percentage of reported research expenditures is 1.1% for the UK, 
1% for Canada, 1.7% for Australia, 1.2% for Europe (ASTP), and 2.9% for the United States. 
 
Insert figure 3 here. 
 
Table 3 shows the relative performance of Europe, the UK, Australia and Canada compared to 
the AUTM results for the US (AUTM equals 1), for all institutes combined and for universities 
only. The only indicator for which the relative performance changes from above or below 1 is 
the number of licenses executed. In this case, Europe outperforms the US when all institutes are 
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 The figure of 1% is obtained from page 29 of the UNICO report. Using the aggregate data in Table 1 for the UK 
gives a rate of 1.6%, which suggests that the rate given in the UNICO study is adjusted for non-response for 
reported license revenues.  
11
 The results for Canada were provided in a special tabulation by Cathy Read from Statistics Canada. Comparable 
data were only available for invention disclosures, patent applications and licenses executed. 
12
 The results for Australia for universities only are not adjusted for missing values.  
13
 According to the HEFCE report, about half of the licenses executed correspond to only two institutions. 
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considered but performs below the US for universities only. All countries except Australia and 
Canada have a higher performance than the US on start-ups. The highest relative performance to 
the US is also observed for this indicator: 3.1 and 2.5 for the UK for all institutes and for 
universities only, respectively, and 2.4 for Europe for universities only. 
 
Insert table 3 here. 
 
4. Discussion 
The six performance indicators given above include three indicators for the potential 
commercialization of public science, invention disclosures, patent applications, and patent 
grants; and three indicators for the actual use of public science discoveries by the business 
sector: licenses executed, start-up establishments, and license revenue. 
 
The value to policy of the three commercial potential indicators is not very high because they do 
not measure the actual uptake of public science results by firms. Their main value to policy is to 
determine the factors that increase the efficiency with which public institutions (primarily 
through their affiliated TTOs) transfer knowledge to the business sector. This requires 
econometric analysis of data at the level of each institution, which requires access to such data. 
This information is reported in the AUTM study for many of the respondents and has been 
extensively analyzed. Phan and Siegel (2006) provide a thorough review of this literature and 
find, not surprisingly, that efficient knowledge transfer depends on the characteristics of the 
institution, such as its research focus, the incentive structure, and organizational characteristics 
of the TTO14. Of this group, the most valuable indicator is for patent grants, particularly if 
combined with additional questions on licensing practices, as discussed below. 
 
The three indicators for the use of public science by firms are inherently more valuable for policy 
because they are closer to measuring the commercialization of public science results15. A 
comparison of national performance on these three indicators is consequently of greater interest 
than a comparison of performance on patent applications or patent grants. Although subject to 
many problems of comparability, the Table 3 summary of the results intriguingly shows that the 
United States is the leader on indicators for commercial potential, particularly patent grants, but 
that its relative performance is more mixed for the three indicators for the use of public science 
by firms, particularly for the number of licenses executed and the number of start-up 
establishments. 
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 Based on a comparative case study of several Canadian universities, Mc. Daniel (2006) concludes that a variety of 
social factors are positively associated with the university’s innovation record. Among other, the university 
receptivity to organizational innovation, the degree to which networking is encouraged and the connection to the 
community are cited as the most important ones. 
15
 None, however, measure successful commercialization. A start-up can fail, a license can lead to nothing of value, 
and even license revenue can be earned without the firm bringing an invention to market or making a profit from it. 
15 
 
The results for the three indicators for the use of public science by firms also suggest that we 
need to take a much more critical look at European assumptions about the causes of the “policy 
paradox”. Europe performs better than the United States on two of the three knowledge transfer 
indicators (and a close second on the third for license revenue as a share of research 
expenditures) for all types of public science institutes combined. The marked weakness for 
European universities for license revenue compared to American universities is partly due to the 
fact that European TTOs that serve universities are much younger than their American 
counterparts and have had less time to develop a licensing portfolio. In the ASTP study, older 
TTOs affiliated to universities earn more license income than younger TTOs16. Furthermore, the 
AUTM sample is likely to contain a higher percentage of the top performing institutes than the 
ASTP sample, so we would have expected the AUTM sample to have better performance than 
the ASTP sample on most indicators. 
 
Some of the differences between the performance indicators for Europe and the United States 
could be due to differences in incentives or ‘environmental’ factors. The higher rate of start-up 
formation in Europe could be due to low royalties for academic inventors. This would provide an 
incentive for academics to establish a firm to exploit their discovery, as found in a study for the 
United States (Di Gregorio and Shane, 2003). Whatever the cause, the high rate of start-up 
formation in Europe suggests that European academics might not be less ‘entrepreneurial” than 
their American counterparts. 
 
4.1 Indicator improvement 
The development of internationally comparable indicators for the commercialisation of public 
science will require the use of standard definitions for output variables and for denominators 
such as research expenditures, similar target populations and survey coverage, and greater 
transparency in the treatment of missing values. In addition, to solving these problems, the time 
causality problem also needs to be addressed. Using research expenditures and outputs for the 
same year implies that the outputs are directly due to the reported research expenditures. This is 
not likely to be the case, with many outputs due to research expenditures over several years. This 
can particularly apply to patent grants, which could be due to research conducted several years 
previously. One possibility is to construct indicators after using different lag times for research 
expenditures, but this might be unnecessarily complex. An alternative for the future is to average 
research expenditures over the previous three years. This is currently only possible for the 
Canadian and AUTM surveys.  
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 On average, only 13% of the ASTP respondent universities were established before 1990, compared to over half 
of the American TTOs. The Pearson correlation coefficient for the age of ASTP TTOs in years and PPP$ of license 
income per PPP$ research expenditures is 0.636 (p=0.000).  
16 
The construction of high quality comparable indicators requires a much higher coverage rate 
than that of the AUTM and ASTP surveys, which is likely to raise serious problems of 
confidentiality. Many public science institutions with poor performance could be reluctant to 
respond if they believe that their results will be made publicly available, possibly leading to a 
reduction in future funding. Yet a failure to include poor performers in surveys will bias the 
results and reduce their value for policy. The ASTP asked respondents if they agreed to have 
their results made public, with 75% refusing. This indicates that the issue of confidentiality must 
be taken seriously in future surveys.  
 
4.2 Other indicators for policy 
The six basic indicators given in this paper can be obtained in a one or two page survey 
questionnaire, based on the questionnaires used in the ASTP and UNICO studies. Since many of 
the national surveys are much longer, ranging from six pages for the AUTM survey to 13 pages 
for Canada, there should be room to collect additional data that could be used to construct 
internationally comparable indicators. We suggest five areas where additional internationally 
comparable data would be of value to policy17.  
 
The first area is to collect data on the number of researchers, preferably in units of time devoted 
to research, to provide an alternative denominator to research expenditures. Units of research 
time could be more comparable internationally than units of research expenditures, which are 
affected by how expenditures are defined and by a lack of purchasing power parity (PPP) 
currency equivalents for research. Furthermore, the ASTP survey found that a higher percentage 
of respondents could provide the number of researchers (73%) than research expenditures (61%). 
The higher response rate for the former could be particularly important for surveys that are not 
compulsory. 
 
The second area is to collect data on who licenses public science inventions – firms based within 
the home country or abroad18, in order to construct an indicator for the percentage of licenses 
that are given domestically. This would serve a basic policy interest in encouraging knowledge 
flows that support domestic economic activity. This question is particularly relevant for 
exclusive licenses, since the main justification for non-exclusive licenses is to raise funds for the 
public institute.  
 
Third, the role of non-exclusive licenses is an important policy issue by itself. Although non-
exclusive licenses can maximize income for the research organization, they could be less 
                                                 
17
 We ignore issues such as whether or not the TTO is financially self-sufficient, such as if the license and IP costs 
are fully covered by license revenue. This is primarily a domestic issue, where internationally comparable data are 
of less value. 
18
 Ownership is less relevant. The key issue is if the location of the development of the licensed invention. 
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effective in transferring knowledge and technology to the business sector than publications that 
make the results freely available to all. Conversely, exclusive licenses for some inventions could 
be absolutely necessary for a firm to invest in developing the invention into a commercial 
product (Colyvas et al, 2000). The disadvantage is that inefficient use of exclusive licensing 
could slow down technical developments and possible social benefits. Indicators for the share of 
exclusive licenses, particularly by technology field, would help policy makers determine if the 
rate of exclusive licensing is above or below the international norm.  
 
Fourth, there is no point in a public science institution applying for IP rights, particularly a 
patent, if the invention is never licensed. This will only increase costs to the institute and 
theoretically, albeit under the unlikely assumption that no firm will infringe the patent, prevent 
firms from using or further developing the patented technology. For this reason it is worthwhile 
to collect data on the percentage of patents that have ever been licensed in order to track changes 
over time and benchmark national performance.  
 
Last, non-patented inventions account for a significant share of licensing activity, even though IP 
policy frequently stresses patents or the need for other strong forms of IP. The OECD study 
(OECD, 2003) found that approximately half of all licenses did not involve a patent, while the 
ASTP study found that 40% of license income in both 2004 and 2005 did not involve a patent. In 
order to keep the role of patents in perspective, it would be worth collecting data on the share of 
licenses and license income that does not involve patents. 
 
5. Conclusions 
This paper shows that it would be possible to obtain internationally comparable indicators for the 
commercialisation of public science with relatively simple agreement over definitions, improved 
survey coverage in Europe and the United States, and a few other ‘tweaks’ to current surveys. In 
addition, the policy relevance could be improved by adding a few additional indicators for who 
licenses, licensing exclusivity, the share of patents that have ever been licensed, and the share of 
licenses and license income from patented and non-patented inventions. 
 
It is important not to lose sight of the fact that the visible and easily measurable output of public 
science institutions, such as patents and licenses, form only part of a large number of activities 
that can lead to commercialisation and social benefits. As noted earlier, useful knowledge can be 
transferred from universities to firms through open science methods such as publications, 
conference presentations, and informal contacts. Two surveys in the early 1990s that were able to 
differentiate between open science and formal methods of knowledge transfer found that both 
European and American firms rate open science more highly as a means of obtaining valuable 
knowledge from public science for their innovative activities than formal methods (Cohen et al. 
2002; Arundel and Geuna, 2004). Similar results have been reported from interviews with MIT 
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staff, which found that patents and licensing are one of the least useful methods of knowledge 
transfer (Agrawal and Henderson, 2002). In Canada, federal departments and agencies have 
experimented with other types of indicators that might be possible to collect from TTOs, such as 
measures of the dissemination of research results to the public (including media coverage, web 
visits, non-scientific publications) and qualitative measures of how research results are used 
(Therrien, 2006).  
 
There is a serious danger that only providing indicators for formal methods of transferring 
knowledge could encourage the policy community to promote formal methods at the expense of 
open science. Phan and Siegel (2006) refer to an unpublished study in the United States by 
Markman, Gianiodis and Phan that found that an increase in professional activities by TTOs 
leads to a fall in informal or ‘bypassing’ linkages between academics and firms. They also report 
that bypassing activities were “associated with more valuable discoveries and heightened 
entrepreneurial activities”. This suggests that the policy community needs to find the optimum 
balance between promoting formal technology transfer methods based on IPR and licensing and 
the informal methods of open science. In this respect, it would be worth developing better 
comparable indicators for the role of open science in the innovative activities of firms. This 
cannot be done through surveys of TTOs, but would require a survey of firms themselves. The 
European Community Innovation Survey (CIS) can provide relevant indicators, such as the 
percentage of firms that give a high importance to knowledge obtained from public research 
organisations. These types of indicators would need to be given equal billing with indicators of 
formal knowledge transfer activities. Perhaps we might find that the cause of any “European 
paradox” is not due to the formal transfer of public science discoveries to firms, where European 
performance appears to be acceptable, but to problems with the system of open science. 
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Table 1. 
 
 
 Definition Compared to AUTM 
United States 
(AUTM) 
Federal and industry sponsored research - 
Europe (ASTP) Total research expenditures Overestimate 
Canada Sponsored research at universities:  conducted under 
contract with the government, Canadian business, 
Canadian organizations, foreign governments, 
foreign businesses, and other foreign organizations. 
It specifically excludes research funded by several 
major federal granting sources. No data for hospitals. 
Underestimate 
UK (UNICO) Not given, but noted from other sources. Estimated 
here from reported ‘research income’ per ₤ license 
income.  
Unknown 
UK (HEFCE) “Total research grants and contracts” including 
“aggregate research funding from OST research 
councils; UK charitable income; UK central 
government; local, health and hospital authorities; 
UK industry, commerce; public corporations; EU 
sources, and other overseas income”. 
Overestimate  
Also includes block 
grants that can be used 
for either teaching or 
research.  
Australia All research and experimental development 
expenditures, using the Frascati definition, including 
capital and labour costs. 
Overestimate  
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Table 2. 
 
 
 
UK-
UNICO 
UK-   
HEFCE Canada 
US 
(AUTM) 
Europe 
(ASTP) Australia 
Fiscal year 2004 2004 2004 2004 2004 2004 
Total reporting institutes 106 162 97 197 101 70 
- of which universities 100     (94%) 
162 
(100%) 
73 
(75%) 
164 
(83%) 
74 
(73%) 
39 
(56%) 
    Survey response rate 56% 100% 69% 65% 59% 89% 
Output indicators (total reported) 
Invention disclosures 2,871 3,029 1,432 16,792 3,481 961 
Priority patent applications 885 884 1,264 13,792 1,616 450 
Patent grants 141 183 158 3,667 320 492 
Licenses executed 1,406 2,154 494 4,758 1,338 383 
Start ups 229 167 40* 462 213 31 
License income (million US PPP$) 65.2 61.79 41.1 1,434.3 190.8 48.2 
 
Research expenditures (million US 
PPP$) 4,062 5,872 4,054 41,244 9,699 4,192 
Sources: Arundel and Bordoy, 2006; AUTM, 2005; Read, 2005; UNICO, 2005, Commonwealth of Australia, 2007, 
HEFCE, 2006. 
(*) Results for start ups are from 2003. 
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Figure 2 
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Figure 3 
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Table 3. 
 
 
 
 ASTP-Europe UK Australia Canada 
 
All 
institutes 
Univ. 
only 
All1 
institutes 
Univ. 
only2 
All 
institutes 
Univ. 
only 
All 
institutes 
Univ. 
only4 
Commercial potential indicators 
Invention disclosures 0.7 0.8 1.1 1.3 0.6 0.6 0.9 0.8 
Patent applications 0.5 0.4 0.5 0.6 - 0.4 1.2 1.2 
Patent grants 0.6 0.4 0.2 0.4 0.6 0.9 1.1 - 
Use indicators 
Licenses executed 1.2 0.8 1.8 3.3 0.8 0.9 1.1 1.0 
Start-ups 1.4 2.4 3.1 2.5 0.6 0.7 0.9 - 
License revenue3 0.9 0.4 0.3 0.4 0.3 0.3 0.3 0.3 
1: UNICO study 
2: HEFCE study 
3: Relative performance for license revenue as a share of reported research expenditures 
4: Source: Special tabulation provided by Cathy Read from Statistics Canada 
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